How many stocks are there of BGI Genomics Co?
The current number of stocks of BGI Genomics Co is 412.34 M undefined.
In 2024, BGI Genomics Co had 412.34 M outstanding stocks, a 0% change from the 412.34 M stocks in the previous year.
YEAR | NUMBER OF STOCKS (undefined CNY) |
---|---|
2025e | 412.34 |
2024e | 412.34 |
2023 | 412.34 |
2022 | 410.37 |
2021 | 411.68 |
2020 | 399.3 |
2019 | 400.1 |
2018 | 400.1 |
2017 | 379.1 |
2016 | 360 |
2015 | 338.6 |
2014 | 244.6 |
3 years
5 years
10 years
25 Years
Max
Revenue per share represents the total revenue BGI Genomics Co earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.
EBIT per share indicates BGI Genomics Co's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.
Income per share, or earnings per share (EPS), reveals the portion of BGI Genomics Co’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.
Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating BGI Genomics Co's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.
Number of stocks | |
---|---|
2014 | 244.6 M Aktien |
2015 | 338.6 M Aktien |
2016 | 360 M Aktien |
2017 | 379.1 M Aktien |
2018 | 400.1 M Aktien |
2019 | 400.1 M Aktien |
2020 | 399.3 M Aktien |
2021 | 411.68 M Aktien |
2022 | 410.37 M Aktien |
2023 | 412.34 M Aktien |
2024e | 412.34 M Aktien |
2025e | 412.34 M Aktien |
BGI Genomics Co's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.
Tracking the changes in BGI Genomics Co’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.
For investors, understanding BGI Genomics Co’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.
Variances in BGI Genomics Co’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.
The current number of stocks of BGI Genomics Co is 412.34 M undefined.
The outstanding shares (or issued shares) of BGI Genomics Co are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.
The number of shares of BGI Genomics Co has increased by 0% gestiegen compared to last year.
The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.
There are various factors that can lead to a change. BGI Genomics Co as a company can issue new shares, carry out stock splits or reverse splits.
There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).
Over the past 12 months, BGI Genomics Co paid a dividend of 1 CNY . This corresponds to a dividend yield of about 2.87 %. For the coming 12 months, BGI Genomics Co is expected to pay a dividend of 1.07 CNY.
The current dividend yield of BGI Genomics Co is 2.87 %.
BGI Genomics Co pays a quarterly dividend. This is distributed in the months of August, August, July, August.
BGI Genomics Co paid dividends every year for the past 8 years.
For the upcoming 12 months, dividends amounting to 1.07 CNY are expected. This corresponds to a dividend yield of 3.07 %.
BGI Genomics Co is assigned to the 'Health' sector.
To receive the latest dividend of BGI Genomics Co from 7/4/2024 amounting to 0.1 CNY, you needed to have the stock in your portfolio before the ex-date on 7/4/2024.
The last dividend was paid out on 7/4/2024.
In the year 2023, BGI Genomics Co distributed 0.35 CNY as dividends.
The dividends of BGI Genomics Co are distributed in CNY.
Our stock analysis for BGI Genomics Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BGI Genomics Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.